Ketamine infusion therapy in treatment-resistant depression
Psychiatriki December 20, 2021 Τheodosios Ε Christodoulakis 1 citation
The FDA has approved S-ketamine nasal spray for treatment-resistant depression, marking a new class of psychiatric drugs. This approval comes 30 years after psychedelics were first studied for mental health treatment. Intravenous ketamine infusion has been researched for depression since the 1990s. The article describes the current protocol for ketamine infusion therapy in patients with treatment-resistant depression and provides related clinical information.